Abstract
In patients with insulin therapy, a simple to use, reliable and safe insulin application device is a prerequisite to achieve good glucose control, and for reducing and avoiding progression of secondary complications. Modern injection pen systems provide the patient with a high degree of flexibility and quality of life. However, the integration of further and appropriate therapeutic aids into a device can make a positive contribution to compliance and therapy satisfaction. In this multicentre, open, randomised, three-month, cross-over study, the new insulin application device Autopen 24® (designed for Sanofi-Aventis insulin cartridges) was evaluated in comparison to the established OptiPen® Pro device with regard to clinical efficacy (HbA1c, frequency of severe hypoglycaemic episodes) and patients' preference and acceptance in 40 patients (20 women, 20 men; 20 type 1, 20 type 2; age [mean±SD] 49.3±15.1 years; BMI 29.0±5.0 kg/m2). No differences were seen regarding HbA1c and hypoglycaemic episodes between the treatment groups. The Autopen 24 showed a high level of acceptance by patients in comparison to OptiPen Pro and was preferred by older patients with type 2 diabetes. In conclusion, Autopen 24 is a suitable alternative to other injection devices in patients with diabetes mellitus treated with Sanofi-Aventis insulin products. Copyright © 2005 John Wiley & Sons, Ltd.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
